kabutan

TAKARA BIO, Net Income Forecast for First Half Loss Widened in Downward Revision

Thu Oct 23, 2025 3:30 pm JST Revision

4974 TAKARA BIO INC. 【J-GAAP】

Guidance Update Report

TAKARA BIO INC. <4974> [TSE Prime] announced a performance revision after the market closed on October 23rd (15:30). The consolidated net income/loss forecast for the cumulative second quarter of the fiscal year ending March 2026 (April to September) has been revised downward from an expected loss of 1.32 billion yen to a loss of 6.90 billion yen (compared to a profit of 0.51 billion yen in the same period of the previous year), indicating an expansion in the loss margin.

Furthermore, the full-year net income forecast remains unchanged from the estimate of 1.30 billion yen(compared to 1.04 billion yen in the previous period).

Kabutan News

Guidance Update

First Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Prev 21,300 -1,450 -1,430 -1,320 -11.0 0 May 13, 2025 J-GAAP
Apr - Sep, 2025 New 18,700 -2,350 -2,500 -6,900 -57.3 0 Oct 23, 2025 J-GAAP
Revision Rate -12.2% -62.1% -74.8% -422.7% -422.8%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 19,758 417 549 513 4.3 0 Nov 8, 2024 J-GAAP
Apr - Sep, 2025 Guidance 18,700 -2,350 -2,500 -6,900 -57.3 0 Oct 23, 2025 J-GAAP
YoY -5.4% － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 43,505 3,003 3,405 1,480 12.3 17 May 10, 2024 J-GAAP
Mar, 2025 45,039 2,263 2,592 1,041 8.7 17 May 13, 2025 J-GAAP
Mar, 2026 Guidance 52,500 2,500 2,500 1,300 10.8 17 May 13, 2025 J-GAAP
YoY +16.6% +10.5% -3.5% +24.9% +24.9%

Related Articles